MicroRNA-361: A Multifaceted Player Regulating Tumor Aggressiveness and Tumor Microenvironment Formation

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Aug 10

PMID 31394811

Citations 14

Authors

Daozhi Xu

Peixin Dong

Ying Xiong

Junming Yue

Kei Ihira

Yosuke Konno

Noriko Kobayashi

Yukiharu Todo

Hidemichi Watari

Affiliations

Soon will be listed here.

Abstract

MicroRNA-361-5p (miR-361) expression frequently decreases or is lost in different types of cancers, and contributes to tumor suppression by repressing the expression of its target genes implicated in tumor growth, epithelial-to-mesenchymal transition (EMT), metastasis, drug resistance, glycolysis, angiogenesis, and inflammation. Here, we review the expression pattern of miR-361 in human tumors, describe the mechanisms responsible for its dysregulation, and discuss how miR-361 modulates the aggressive properties of tumor cells and alter the tumor microenvironment by acting as a novel tumor suppressor. Furthermore, we describe its potentials as a promising diagnostic or prognostic biomarker for cancers and a promising target for therapeutic development.

Citing Articles

Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma.

Fotia G, Stellato M, Guadalupi V, Sepe P, Claps M, Giannatempo P Curr Oncol Rep. 2023; 25(6):671-677.

PMID: 37000341 DOI: 10.1007/s11912-023-01395-4.

Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways.

Janowski M, Ulanczyk Z, Luczkowska K, Sobus A, Roginska D, Pius-Sadowska E Onco Targets Ther. 2022; 15:1123-1141.

PMID: 36238136 PMC: 9553433. DOI: 10.2147/OTT.S371847.

Integrated analysis using ToppMiR uncovers altered miRNA- mRNA regulatory networks in pediatric hepatocellular carcinoma-A pilot study.

Whyte S, Karns R, Min K, Cho J, Lee S, Lake C Cancer Rep (Hoboken). 2022; 6(1):e1685.

PMID: 35859536 PMC: 9875636. DOI: 10.1002/cnr2.1685.

miR-30d-5p: A Non-Coding RNA With Potential Diagnostic, Prognostic and Therapeutic Applications.

Zhao Q, Yuan X, Zheng L, Xue M Front Cell Dev Biol. 2022; 10:829435.

PMID: 35155437 PMC: 8829117. DOI: 10.3389/fcell.2022.829435.

The Role of the SOX9/lncRNA ANXA2P2/miR-361-3p/SOX9 Regulatory Loop in Cervical Cancer Cell Growth and Resistance to Cisplatin.

He S, Feng Y, Zou W, Wang J, Li G, Xiong W Front Oncol. 2022; 11:784525.

PMID: 35083143 PMC: 8784813. DOI: 10.3389/fonc.2021.784525.

References

Salinas-Vera Y, Marchat L, Gallardo-Rincon D, Ruiz-Garcia E, Astudillo-de la Vega H, Echavarria-Zepeda R . AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review). Int J Mol Med. 2018; 43(2):657-670. DOI: 10.3892/ijmm.2018.4003. View

Scholl V, Hassan R, Zalcberg I . miRNA-451: A putative predictor marker of Imatinib therapy response in chronic myeloid leukemia. Leuk Res. 2011; 36(1):119-21. DOI: 10.1016/j.leukres.2011.08.023. View

Tian L, Zhao Z, Xie L, Zhu J . MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget. 2018; 9(4):4886-4896. PMC: 5797020. DOI: 10.18632/oncotarget.23513. View

Ihira K, Dong P, Xiong Y, Watari H, Konno Y, Hanley S . EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis. Oncotarget. 2017; 8(8):13509-13520. PMC: 5355116. DOI: 10.18632/oncotarget.14586. View

Kanitz A, Imig J, Dziunycz P, Primorac A, Galgano A, Hofbauer G . The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma. PLoS One. 2012; 7(11):e49568. PMC: 3498195. DOI: 10.1371/journal.pone.0049568. View

Zhang X, Wei C, Li J, Liu J, Qu J . MicroRNA-361-5p inhibits epithelial-to-mesenchymal transition of glioma cells through targeting Twist1. Oncol Rep. 2017; 37(3):1849-1856. DOI: 10.3892/or.2017.5406. View

Koutova L, Sterbova M, Pazourkova E, Pospisilova S, Svobodova I, Horinek A . The impact of standard chemotherapy on miRNA signature in plasma in AML patients. Leuk Res. 2015; 39(12):1389-95. DOI: 10.1016/j.leukres.2015.08.009. View

Sun J, Chen G, Xie Z . MicroRNA-361-5p Inhibits Cancer Cell Growth by Targeting CXCR6 in Hepatocellular Carcinoma. Cell Physiol Biochem. 2016; 38(2):777-85. DOI: 10.1159/000443033. View

Yang S, Zhang Y, Zhao X, Wang J, Shang J . microRNA-361 targets Wilms' tumor 1 to inhibit the growth, migration and invasion of non-small-cell lung cancer cells. Mol Med Rep. 2016; 14(6):5415-5421. DOI: 10.3892/mmr.2016.5858. View

10.

Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C . Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018; 17(1):45. PMC: 5817860. DOI: 10.1186/s12943-018-0796-y. View

11.

Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S . Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer. Oncogene. 2018; 37(39):5257-5268. PMC: 6160397. DOI: 10.1038/s41388-018-0347-4. View

12.

Inns J, James V . Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease. Breast. 2015; 24(4):364-9. DOI: 10.1016/j.breast.2015.04.001. View

13.

Schwarzenbach H, Nishida N, Calin G, Pantel K . Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-56. DOI: 10.1038/nrclinonc.2014.5. View

14.

Lee R, Ambros V . An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001; 294(5543):862-4. DOI: 10.1126/science.1065329. View

15.

Wang J, Lu Y, Wang J, Koch A, Zhang J, Taichman R . CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res. 2008; 68(24):10367-76. PMC: 2884407. DOI: 10.1158/0008-5472.CAN-08-2780. View

16.

Jang M, Kim S, Lee J . Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med. 2013; 45:e45. PMC: 3809361. DOI: 10.1038/emm.2013.85. View

17.

Li R, Dong B, Wang Z, Jiang T, Chen G . RETRACTED: MicroRNA-361-5p inhibits papillary thyroid carcinoma progression by targeting ROCK1. Biomed Pharmacother. 2018; 102:988-995. DOI: 10.1016/j.biopha.2018.03.122. View

18.

Bouchie A . First microRNA mimic enters clinic. Nat Biotechnol. 2013; 31(7):577. DOI: 10.1038/nbt0713-577. View

19.

Liu J, Yang J, Yu L, Rao C, Wang Q, Sun C . miR-361-5p inhibits glioma migration and invasion by targeting SND1. Onco Targets Ther. 2018; 11:5239-5252. PMC: 6118279. DOI: 10.2147/OTT.S171539. View

20.

Rupaimoole R, Calin G, Lopez-Berestein G, Sood A . miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016; 6(3):235-46. PMC: 4783232. DOI: 10.1158/2159-8290.CD-15-0893. View